Are serum levels of inflammatory markers associated with the severity of symptoms of bipolar disorder?
Open accessThe DOI matches its Crossref record; 58 of the 62 references it cites were found in a registry or an index, and 2 are not checked yet; 3 of the 22 sources its claims cite were checked for support.
Abstract
Background: To explore the relationship between serum levels of inflammatory markers and symptomatic severity of bipolar disorder (BD). Materials and methods: A cross-sectional study was conducted on 126 BD patients with current depressive episode (BDD), 102 BD patients with current mixed or (hypo)manic episode (BDM) and 94 healthy controls (HC). All participants were drug-naïve and had no current active physical illness associated with inflammatory response or history of substance abuse. Fasting serum levels of CRP, leptin (LEP), adiponectin (ADP), visfatin (VIS), TNF-α, IL-2, IL-6, IL-10, IL-17), and monocyte chemoattractant protein-1 (MCP-1) were measured with enzyme-linked immunosorbent assay (ELISA). Symptomatic severity of BD was assessed with HAMD-17 and YMRS. Generalized linear model was used to determine the association between the serum levels of inflammatory markers and symptomatic severity of BD. Results: The serum levels of IL-6, IL-10 and IL-17, and the IL-6/IL-10 ratio were significantly lower in mild BDD than in HC. In moderate BDD, the serum levels of MCP, IL-6 and IL-17 were significantly lower than in HC. In severe BDD, the serum level of ADP, MCP-1, IL-10 and IL-17and the IL-17/IL-10 ratio were significantly lower than in HC. The serum levels of TNF-α and the IL-6/IL-10 ratio were significantly higher in mild BDM than in HC. In moderate BDM, the serum level of VIS, IL-2, and IL-17 were significantly higher than in HC, but the IL-6/IL-10 ratio was significantly lower than in control. In severe BDM, the serum levels of IL-6 and IL-17 and the ratios of IL-6/IL-10 and IL-17/IL-10 were significantly lower than in HC, but the neutrophil/lymphocyte ratio was significantly higher than in HC. Conclusion: In BDD, immune-inhibition is persistently predominant, while in mild-to-moderate BDM, immune system is activated but inhibited in severe BDM. The dynamic change of serum inflammatory markers suggests that alteration of peripheral inflammatory markers in BD is state-dependent instead of trait-marked.
Verified 2026-10-05 · 2 references not checked yet
Overview
CoChat Summary
TL;DR
In a cross-sectional study of 228 drug-naïve bipolar disorder (BD) patients and 94 healthy controls, serum inflammatory markers varied by episode type and symptom severity: bipolar depression showed persistent immune-inhibition, while (hypo)manic/mixed episodes showed activation in mild-to-moderate states and inhibition in severe states. The authors conclude that peripheral inflammatory alterations in BD are state-dependent rather than trait-marked.
Key findings
- In bipolar depressive episode (BDD), most observed markers decreased versus healthy controls (HC): mild BDD had lower IL-6, IL-10, and IL-17; moderate BDD had lower MCP, IL-6, and IL-17; severe BDD had lower ADP, MCP-1, IL-10, and IL-17, plus a lower IL-17/IL-10 ratio.
- In (hypo)manic/mixed episode (BDM), mild BDM had higher TNF-α and a lower IL-6/IL-10 ratio; moderate BDM had higher VIS, IL-2, and IL-17 but a lower IL-6/IL-10 ratio; severe BDM had lower IL-6, IL-17, IL-6/IL-10, and IL-17/IL-10, but a higher neutrophil/lymphocyte ratio.
- The authors report that immune-inhibition is persistently predominant in BDD, whereas BDM shows immune activation in mild-to-moderate severity and inhibition in severe severity.
Methods
- Cross-sectional study of 126 BD patients with current depressive episode, 102 BD patients with current mixed or (hypo)manic episode, and 94 healthy controls; participants were Han Chinese, aged 16–65, drug-naïve, without current active physical illness associated with inflammatory response, and without psychoactive substance abuse in the past six months.
- Fasting serum levels of CRP, leptin, adiponectin, visfatin, TNF-α, IL-2, IL-6, IL-10, IL-17, and MCP-1 were measured by ELISA; symptomatic severity was assessed with HAMD-17 and YMRS.
- Generalized linear models assessed associations between inflammatory markers and symptom severity, adjusting for age, gender, marital status, BMI, education, and severity of manic or depressive symptoms, with Bonferroni-adjusted significance testing.
Limitations
- The paper states that the cross-sectional design limits causal conclusions; some potential confounders such as cognitive symptoms and atypical features were not assessed; the sample may still be too small to detect small but clinically meaningful effects, especially in subgroups; some inflammatory marker data were too dispersed to build a good generalized linear model; no patients in remission were enrolled; and only serum markers, not central nervous system markers, were measured.
- Evident from the text: the sample was Han Chinese, recruited from one hospital and local community, and mostly young, which may limit generalizability to other populations or older patients.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
2 Valid · 0 Not valid · 9 Not checked · 60 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“growing and converging evidence has demonstrated that immune dysfunction is involved in the pathophysiology of BD (1).”
§ Are serum levels of inflammatory markers associated with the severity of symptoms of bipolar disorder? > Background
What the sources say
- Supportedcites [1] Rosenblat, 2017, Bipolar disorder and immune dysfunction: epidemiological findings, proposed pathophysiology and clinical implications., Brain Sci. source
The Introduction (Section 1) states plainly that 'More recently, immune dysfunction has been implicated in the patho-etiology of BD,' and the paper devotes Section 4 to the 'Pathophysiology of the Inflammatory-Mood Pathway' in BD, with the Abstract and Conclusions (Section 6) affirming that BD is strongly associated with immune dysfunction and that immune dysfunction plays a role in disease pathophysiology. The only nuance is one of magnitude: the source hedges that a key pathophysiologic role is 'likely' confined to 'a subset of BD' (Abstract; Section 3, p. on cytokine heterogeneity), whereas the citing sentence states involvement without that subset qualifier. The content attributed — involvement of immune dysfunction in BD pathophysiology, supported by accumulating epidemiological, cytokine and mechanistic evidence — is what our copy argues throughout. (LLM, conf=0.85)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This inconsistency is thought to be attributed to heterogeneity between studies, insufficient standardization and lacking control for confounders (2), including gender (6), age (7), marital status (8), body mass index (BMI) (9), psychoactive substance abuse (6), atypical features (10), duration of illness (11), pharmaceutical treatment (12, 13), and so on.”
§ Are serum levels of inflammatory markers associated with the severity of symptoms of bipolar disorder? > Background
What the sources say
- Not checked yetcites [2] Munkholm, 2013, Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis., J Psychiatr Res. source
- Partly supportedcites [6] Gonzalez-Quintela, 2008, Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities., Clin Exp Immunol. sourceExperimental — accuracy not yet measured
Citation (9) is attached specifically to BMI. The Results (Table 2; page unavailable) compare immunoglobulin levels across BMI categories, and the Introduction calls for accounting for confounding among factors associated with those levels. The paper does not study bipolar disorder or show that BMI explains inconsistent findings on inflammatory markers in that disorder. (LLM, conf=0.82)
- Could not verifycites [7] Osimo, 2018, Prevalence and correlates of low-grade systemic inflammation in adult psychiatric inpatients: an electronic health record-based study., Psychoneuroendocrinology. sourceExperimental — accuracy not yet measured
Citation (2) is attached to the proposed explanation for inconsistent findings: study heterogeneity, insufficient standardization, and lack of confounder control. The Discussion identifies demographic and clinical correlates of inflammation and limitations of this study, but does not attribute inconsistencies between bipolar-disorder studies to those methodological issues. I searched for heterogeneity, standardization, and confounder control across studies; the separately cited list of specific confounders is not the claim assigned to this source. (LLM, conf=0.74)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In mild BDM, only the serum level of TNF-α (P < 0.001, OR = e1.000 = 2.718, 95%CI = e0.490-e1.511 = 1.632-4.531) was significantly higher than that in HC”
§ Are serum levels of inflammatory markers associated with the severity of symptoms of bipolar disorder? > Results > The association between severity of manic symptoms and serum level of inflammatory markers
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“IL-10(P = 0.002, OR = e–1.069 = 0.343, 95%CI = e–1.746-e–0.393 = 0.174-0.675)”
§ Are serum levels of inflammatory markers associated with the severity of symptoms of bipolar disorder? > Results > The association between severity of depressive symptoms and serum level of inflammatory markers
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The serum levels of TNF-α and the IL-6/IL-10 ratio were significantly higher in mild BDM than in HC.”
§ Are serum levels of inflammatory markers associated with the severity of symptoms of bipolar disorder? > Abstract > Results
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
39 more claims
Create a free account to see all 71 claims and to verify the 19 references still open.
- The quote only partly states this claim. 2
- It may state two separate claims as one. 17
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, Wu et al. reported progressively declining levels of pro-inflammatory (such as IL-6, IL-17, and monocyte chemoattractant protein-1 (MCP-1)) and anti-inflammatory (e.g., IL-10) cytokines as the severity of bipolar depression increases, indicating a downward trajectory from mildly blunted immune activation to complete dysregulation (or”
From Complete blood count-based inflammation indexes and symptom severity in people with bipolar disorder: an analysis based on structural equation modelling (2026) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“−0.150 | −0.526 | −0.226 | 0.434”
§ Are serum levels of inflammatory markers associated with the severity of symptoms of bipolar disorder? > Results > The association between severity of manic symptoms and serum level of inflammatory markers
Reported -0.15 · recomputed -0.376
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Are serum levels of inflammatory markers associated with the severity of symptoms of bipolar disorder? > Results > The association between severity of depressive symptoms and serum level of inflammatory markers
“1.0-2430.0”
§ Are serum levels of inflammatory markers associated with the severity of symptoms of bipolar disorder? > Results > The association between severity of depressive symptoms and serum level of inflammatory markers
“4114.0”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Are serum levels of inflammatory markers associated with the severity of symptoms of bipolar disorder? > Results > Demographic and clinical characteristics of participants
“The level of education and the proportion of female participants among BDD were significantly lower than those among HC (P < 0.001)”
§ Are serum levels of inflammatory markers associated with the severity of symptoms of bipolar disorder? > Results > Demographic and clinical characteristics of participants
“| Female n(%) | 65(51.6) | 66 (64.7) | 68(72.3) | 0.002 | 0.284 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Are serum levels of inflammatory markers associated with the severity of symptoms of bipolar disorder? > Results > Demographic and clinical characteristics of participants
“Compared to HC, BDM was younger (P < 0.001)”
§ Are serum levels of inflammatory markers associated with the severity of symptoms of bipolar disorder? > Results > Demographic and clinical characteristics of participants
“| Age (mean ± SD)(year) | 27.8 ± 10.7 | 25.4 ± 8.1 | 29.6 ± 11.0 | 0.241 | 0.002 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Are serum levels of inflammatory markers associated with the severity of symptoms of bipolar disorder? > Results > The association between severity of depressive symptoms and serum level of inflammatory markers
“the serum level of ADP (P = 0.002, OR = e–0.81 = 0.445, 95%CI = e–0.915-e–0.199 = 0.400-0.820), MCP-1(P < 0.001, OR = e–0.557 = 0.573, 95%CI = e–1.179-e–0.44 = 0.308-0.644)”
§ Are serum levels of inflammatory markers associated with the severity of symptoms of bipolar disorder? > Results > The association between severity of depressive symptoms and serum level of inflammatory markers
“| MCP-15 | 210 | 1.730 | <0.001 | −0.904 | −1.592 | −0.215 | 0.010 | −0.733 | −1.194 | −0.272 | 0.002 | −0.810 | −1.179 | −0.440 | < 0.001 |”
3 more findings
Create a free account to see every finding of this check.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 3×
“The symptomatic severity of BD was evaluated with the 17- item Hamilton Depression Scale (HAMD-17) (26) and the Young Mania Rating Scale (YMRS) (27).”
MethodMcCullagh, P., & Nelder, J. A. (1989) · doi:10.1007/978-1-4899-3242-6 · Cited by 16,836
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852 · cited 1×
“Patients with current mixed episode was classified as (hypo) manic group, considering the number of patients with current (hypo)manic episode was small in this study and (hypo)manic and mixed episode shared similar treatment strategy (29).”
ResultGoldsmith, D. R., Rapaport, M. H., & Miller, B. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.3 · Cited by 1,683
Severity classification on the Hamilton depression rating scale
Zimmerman, M., Martinez, J. H., Young, D., Chelminski, I., & Dalrymple, K. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.04.028 · Cited by 1,199 · cited 2×
“Symptomatic severity of BD was assessed with HAMD- 17 and YMRS.”
Gonzalez-Quintela, A., Alende, R., Gude, F., Campos, J., Rey, J., Meijide, L. M., Fernandez-Merino, C., & Vidal, C. (2007) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2007.03545.x · Cited by 630
Cytokine Alterations in Bipolar Disorder: A Meta-Analysis of 30 Studies
Modabbernia, A., Taslimi, S., Brietzke, E., & Ashrafi, M. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.01.007 · Cited by 596
Inflammation in Depression and the Potential for Anti-Inflammatory Treatment
Kohler, O., Krogh, J., Mors, O., & Eriksen Benros, M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151208113700 · Cited by 516 · cited 6×
“In recent years, antiinflammatory agents were expected to be a promising treatment target of MDD (39) and BDD (40).”
BackgroundInfluential
Cited by
Beunders, A. J. M., Orhan, M., & Dols, A. (2023) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000883 · Cited by 45
Filho, A. J. M. C., Eyres, C., Blöbaum, L., Landwehr, A., & Tremblay, M. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16098 · Cited by 34
Pantović-Stefanović, M., Velimirović, M., Jurišić, V., Puric, M., Gostiljac, M., Dodić, S., Minic, I., Nesic, M. J., Nikolić, T., Petronijević, N., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-73937-0 · Cited by 19
Role of interleukin 17 (IL-17) in the inflammatory hypothesis of depression
Bliźniewska-Kowalska, K. M., Halaris, A. E., Gałecki, P., & Gałecka, M. (2023) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2023.100610 · Cited by 15
Metabolic Syndrome and Adipokines Profile in Bipolar Depression
Bilska, K., Dmitrzak‐Węglarz, M., Osip, P., Pawlak, J., Paszyńska, E., & Permoda-Pachuta, A. (2023) · Nutrients · doi:10.3390/nu15214532 · Cited by 12
Metadata
- Authors
- Wu, X., Chen, Z., Liao, Y., Yang, Z., Liang, X., Guan, N., & Gan, Z.
- Affiliations
- Third Affiliated Hospital of Sun Yat-sen University (CN)
- Corresponding author
- Guan, Nianhong
- Gan, Zhaoyu
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2023-01-20
- Volume
- 13
- Pages
- 1063479-1063479
- ISSN
- 1664-0640 (ISSN-L)
- PMC
- PMC9894870
- OpenAlex
- W4317513111
- Cited by
- 23
- References
- 62
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 5 · 2023: 4
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Psychiatry (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Natural Science Foundation of Guangdong Province
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- bipolar disorder, inflammatory markers, serum cytokines, symptom severity, depressive episodes, manic episodes, mixed states, interleukin-6, IL-10, IL-17, IL-6/IL-10 ratio, MCP-1, TNF-α, leptin, adiponectin, visfatin, neutrophil-to-lymphocyte ratio, immune activation, C-reactive protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Are serum levels of inflammatory markers associated with the severity of symptoms of bipolar disorder? https://app.cochat.ai/papers/10.3389/fpsyt.2022.1063479
- The paper
- Wu, X., Chen, Z., Liao, Y., Yang, Z., Liang, X., Guan, N., & Gan, Z. (2023). Are serum levels of inflammatory markers associated with the severity of symptoms of bipolar disorder? Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2022.1063479
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.